Indivior PLC (the
"Company")
Indivior's primary listing now on the Nasdaq Stock
Market
June 27, 2024
The Company announces that its
primary listing is now on the Nasdaq Stock Market ("Nasdaq"). This
follows the transfer of the Company's listing category on the
Official List of the U.K. Financial Conduct Authority from "Premium
Listing (commercial company)" to "Standard Listing (shares)" as of
08.00 a.m. U.K. / 03.00 a.m. ET today. The Company's shares remain
eligible for and continue to trade on the Main Market of the London
Stock Exchange ("LSE") as a Standard Listing segment
issuer.
On February 22, 2024, the Board
announced its intention to consult with shareholders about the
proposed relocation of the Company's primary listing from the U.K.
to the U.S. Having completed the consultation, the Board
announced on April 25, 2024 that, following careful consideration
of the feedback received, it had decided to seek the approval of
shareholders for the proposed transfer of its primary listing.
On May 23, 2024, shareholders passed the special
resolution to transfer the Company's listing category from a
Premium Listing to a Standard Listing on the LSE, which has taken
effect today. With immediate effect therefore, the Company's
primary listing is on Nasdaq.
Graham Hetherington, Chair, said:
"We are pleased to achieve this key milestone
for Indivior. A U.S. primary listing on Nasdaq best reflects the
profile of Indivior's business, which is focused on growing its
leadership position in the U.S. addiction treatment market. We
appreciate the strong support received from shareholders for this
initiative and look forward to capitalizing on the expected
benefits of this move, including greater investor awareness of
Indivior's leadership position in addiction treatment and its
opportunities for continued strong growth."
Key
Contacts:
Jason Thompson
VP, Investor Relations
+1 804-402-7123
or jason.thompson@indivior.com
Tim Owens
Director, Investor
Relations
+1 804-263-3978
or timothy.owens@indivior.com
Kathryn Hudson
Company Secretary
+44 (0)1753 423940
or kathryn.hudson@indivior.com
Indivior PLC's Legal Entity
Identifier code is 213800V3NCQTY7IED471.
About Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD) and serious mental
illnesses. Our vision is that all patients around the world will
have access to evidence-based treatment for the chronic conditions
and co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States in Richmond, VA,
Indivior employs over 1,100 individuals globally and its portfolio
of products is available in 37 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/
company/indivior.
Important Cautionary
Note Regarding Forward Looking Statements
This presentation contains certain
statements that are forward-looking. Forward-looking statements
include, among other things, statements regarding future growth,
the expected benefits of a U.S. primary listing, and other
statements containing the words "believe," "anticipate,"
"plan," "expect," "intend," "estimate," "forecast,"
"strategy," "target," "guidance," "outlook," "potential,"
"project," "priority," "may," "will," "should," "would," "could,"
"can," "outlook," "guidance," the negatives thereof, and
variations thereon and similar expressions. By their nature,
forward-looking statements involve risks and uncertainties as they
relate to events or circumstances that may or may not occur in
the future.
Actual results may differ materially
from those expressed or implied in such statements. Various factors
may cause differences between Indivior's expectations and
actual results, including, among others, the risks associated with the
relocation of our primary listing to the US and any volatility in
our share price and shareholder base in connection therewith;
weakness in the economy, market trends, uncertainty and other
conditions in the markets in which we operate, and other factors
beyond our control, including any macroeconomic or other
consequences of the current armed conflicts; our ability or
inability to execute our strategic priorities; and the risks set
forth in our annual report on Form 20-F filed with the Securities
and Exchange Commission on March 6, 2024, under the heading "Risk
Factors."
Forward-looking statements speak
only as of the date that they are made and should be regarded
solely as our current plans, estimates and beliefs. Except as
required by law, we do not undertake and specifically decline
any obligation to update, republish or revise forward-looking
statements to reflect future events or circumstances or to reflect
the occurrences of unanticipated events.